Legend Biotech was featured in Scientific American, where we discussed the success of CAR-T cell therapies in transforming the treatment paradigm for #MultipleMyeloma. Learn how we are racing to treat more patients faster: https://lnkd.in/eC_iEmMc #CellTherapy #CART
Legend Biotech’s Post
More Relevant Posts
-
Quick read and insightful look into how CAR-T is transforming the treatment of cancer.
Legend Biotech was featured in Scientific American, where we discussed the success of CAR-T cell therapies in transforming the treatment paradigm for #MultipleMyeloma. Learn how we are racing to treat more patients faster: https://lnkd.in/eC_iEmMc #CellTherapy #CART
CAR-T Cells Approach Cancer’s Front Lines
scientificamerican.com
To view or add a comment, sign in
-
EMEA Cell Culture Applications Manager I Cell and Gene Therapy Champion I Business Development I Marketing I Scientific Affairs I Collaborations
Investigation of long term effects for any type of new treatments, especially involving #ATMPs is critical, #cellandgenetherapies are complex, relatively new and come with many challenges on the way, #FDA actions are totally understandable, it’s necessary to keep learning and to make any type of therapies even safer and more standardised for future generations
District Manager - Leading the Bay Area field team to enable cutting edge science - Thermo Fisher Scientific
Interesting week in Cell Therapy after the FDA announced they will be looking into the risk of T-cell malignancies. Although additional investigation may be waranted I still have great cofidence in these therapies. This is a great summary article from Science which captured the fields reaction to the news: https://lnkd.in/gtiqsttj.
Explainer: What’s behind FDA’s concern that a cancer-fighting cell therapy can also cause the disease?
science.org
To view or add a comment, sign in
-
Happy Monday all! Check out this open access Frontiers in Immunotherapy article by Maria Letizia Giardino Torchia and Gordon Moody where they develop a tool to characterize adoptive cell immunotherapies. "The acronym DIAL stands for Distribution, Infiltration, Accumulation, and Longevity, compartmentalizing the systemic attributes of gene-modified cellular therapy and providing a platform for optimization with the ultimate goal of improving therapeutic efficacy. This review will discuss both existent and emerging examples of DIAL characterization in mouse models, as well as opportunities for future development and optimization." #drugdiscovery #drugdevelopment #immunotherapy #cancerresearch #immunooncology #scientificresearch #cartcelltherapy #sciencecommunication
Frontiers | DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies
frontiersin.org
To view or add a comment, sign in
-
Dr. Divya S. Mishra, a Board-Certified Oncologist, explores the exciting potential of #Redoxhomeostasis in #cancertreatment. New research from Tata Medical Centre is investigating #nutraceutical combinations to improve outcomes and manage treatment toxicity. This focus on cellular foundation holds immense promise for cancer patients worldwide. Insightful Article: https://lnkd.in/gJfguXFT #clinicaltrials #clinicalresearch #cancerresearch
The Potential of Cell Free Chromatin Inhibition in Cancer
pharmafocusasia.com
To view or add a comment, sign in
-
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy https://lnkd.in/g2TyeCQX
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy
pubs.acs.org
To view or add a comment, sign in
-
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy https://lnkd.in/g2TyeCQX
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy
pubs.acs.org
To view or add a comment, sign in
-
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy https://lnkd.in/g2TyeCQX
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy
pubs.acs.org
To view or add a comment, sign in
-
In this GEN Keynote webinar, experts are discussing emerging cell therapies outside of CAR-T
The Evolving Landscape of Cell Therapies Beyond CAR-T
genengnews.com
To view or add a comment, sign in
-
#AI is changing the game in #medicine! From crafting new drugs for idiopathic pulmonary fibrosis to predicting treatment responses in head and neck cancer patients, #AI is accelerating #treatment #discovery and improving #patientcare and outcomes. How do you think AI will continue to shape the #future of healthcare? Share your thoughts! #AIinMedicine #TreatmentAdvancements #nvidia #insilicomedicine #Lunit https://lnkd.in/gjMDzQxe
AI-Driven Breakthroughs in Drug Discovery and Treatment Optimization - GeneOnline News
geneonline.com
To view or add a comment, sign in
-
Are cell therapies ready for prime time? This article explores ways to make cell therapies more widely used. Thanks Neil Sheppard D.Phil & Jeanne Loring for your insights!
Challenges and Solutions in Cell Therapy Development
technologynetworks.com
To view or add a comment, sign in
75,294 followers
Physician Assistant at Astellas Pharma US
2moThank you Legend Biotech for changing the course in Multiple Myeleoma